Novartis says U.S. regulator grants speedy review of CAR-T cell therapy

ZURICH (Reuters) - Novartis AG on Wednesday said the U.S. Food and Drug Administration (FDA) has agreed to accelerate its review of the Swiss drugmaker's CTL019 therapy for young patients with B-cell acute lymphoblastic leukemia.